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The energy-sensing AMP-activated protein kinase
(AMPK) is activated by low nutrient levels. Functions
of AMPK, other than its role in cellular metabolism,
are just beginning to emerge. Here we use a chemical
genetics screen to identify direct substrates of AMPK
in human cells. We find that AMPK phosphorylates
28 previously unidentified substrates, several of
which are involved in mitosis and cytokinesis. We
identify the residues phosphorylated byAMPK in vivo
in several substrates, including protein phosphatase
1 regulatory subunit 12C (PPP1R12C) and p21-acti-
vated protein kinase (PAK2). AMPK-induced phos-
phorylation is necessary for PPP1R12C interaction
with 14-3-3 and phosphorylation of myosin regula-
tory light chain. Both AMPK activity and PPP1R12C
phosphorylation are increased in mitotic cells and
are important for mitosis completion. These findings
suggest that AMPK coordinates nutrient status with
mitosis completion, which may be critical for the
organism’s response to low nutrients during devel-
opment, or in adult stem and cancer cells.
INTRODUCTION
The ability to rapidly respond to changes in energy levels is
essential for cells and organisms. AMPK plays a central role in
the maintenance of energy homeostasis (Kahn et al., 2005) and
has been implicated in longevity and tumor suppression (Apfeld878 Molecular Cell 44, 878–892, December 23, 2011 ª2011 Elsevieret al., 2004; Greer et al., 2007a;Mair et al., 2011; Shackelford and
Shaw, 2009). AMPK is a conserved heterotrimeric serine/threo-
nine protein kinase composed of a catalytic a subunit, a scaf-
folding b subunit, and a regulatory g subunit. AMPK is activated
bya rangeof stimuli, includingnutrient deprivation, exercise, anti-
diabetic drugs, and cellular stresses, which lead to an increase
in the AMP:ATP ratio (Kahn et al., 2005). AMP binding to the
g subunit activates AMPK by allosterically activating the kinase
and facilitating phosphorylation by upstream kinases (Hardie
et al., 1999; Hawley et al., 2005), and by inhibiting dephos-
phorylation by protein phosphatases (Sanders et al., 2007b).
Once activated, AMPK phosphorylates a number of
substrates involved in metabolic regulation, including acetyl-
CoA carboxylase 1 (ACC1), to induce ATP production and
restore energy levels (Witters and Kemp, 1992; Woods et al.,
1994). AMPK also phosphorylates several proteins in the TOR
signaling pathway, including TSC2 (Inoki et al., 2003) and Raptor
(Gwinn et al., 2008), resulting in the inhibition of protein transla-
tion, a high energy-consuming pathway. AMPK regulates gene
expression through the phosphorylation of transcription factors
(e.g., FOXO3 [Greer et al., 2007b]), coactivators (e.g., CRTC2
[Koo et al., 2005; Shaw et al., 2005]), histone deacetylases
(Mihaylova et al., 2011), and histones (Bungard et al., 2010).
AMPK has been proposed to promote cell-cycle arrest at the
G1 phase via phosphorylation of tumor suppressors such as
p53 (Imamura et al., 2001; Jones et al., 2005), Rb (Dasgupta
and Milbrandt, 2009), and p27Kip1 (Liang et al., 2007), although
the phosphorylation site in some of these substrates diverges
from the AMPK consensus motif (Gwinn et al., 2008). Emerging
evidence suggests that AMPK might also regulate mitosis in
Drosophila and human cells (Bettencourt-Dias et al., 2004; Das-
gupta and Milbrandt, 2009; Lee et al., 2007; Vazquez-MartinInc.
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role in mitotic progression and the mechanisms by which AMPK
might control mitosis are not known.
Identifying substrates of AMPK in a systematic manner is
a key step in understanding the cellular processes controlled
by this energy-sensing protein kinase. Here we used a chemical
genetic screen to identify direct in vivo substrates of one of the
catalytic subunits of AMPK, AMPKa2, in human cells. We
discovered 28 previously unidentified AMPK substrates that
are enriched for proteins involved in chromosomal segregation,
mitosis, cytokinesis, and cytoskeletal reorganization. We
focused on two substrates, protein phosphatase 1 regulatory
subunit 12C (PPP1R12C) and p21-activated protein kinase
(PAK2), because they are both involved in the regulation of
myosin regulatory light chain (MRLC), a crucial protein for mitotic
progression. We found that AMPK is important for the phos-
phorylation of PPP1R12C and PAK2 in cells. Phosphorylation
of PPP1R12C by AMPK is required for 14-3-3 binding and
complete induction of MRLC phosphorylation. Both AMPK
activity and phosphorylation of PPP1R12C are elevated during
mitosis and are important for mitotic progression. Thus, AMPK
coordinates a network of proteins involved in mitosis comple-
tion, which may be essential for normal development, stem cell
self-renewal, and cancer progression.
RESULTS
An Analog-Specific Mutant of AMPKa2 Can Use Bulky
ATP Analogs
To identify direct substrates of AMPKa2 in vivo, we used a
chemical genetics approach (Alaimo et al., 2001). This approach
is based on the fact that the ATP-binding pocket of protein
kinases contains a conserved ‘‘gatekeeper residue’’ in close
contact with the N6 position of the adenine ring of ATP. Replace-
ment of this gatekeeper residue with a smaller amino acid
enables the mutant protein kinase (termed ‘‘analog-specific’’)
to use ATP analogs containing bulky groups at the N6 position
(Allen et al., 2007) (Figure 1A). In contrast, the bulky ATP analogs
are poor substrates for wild-type (WT) kinases due to the steric
hindrance of the gatekeeper residue. N6-modified ATPgS
nucleotides are also accepted by the analog-specific kinase,
and the transferred thiophosphate can be alkylated and recog-
nized by a specific monoclonal antibody (Figure 1A) (Allen
et al., 2005, 2007). This chemical genetic approach allows
specific labeling of direct substrates of a protein kinase in cells.
Alignment of the amino acid sequence of human AMPKa2
with that of other protein kinases for which analog-specific
versions have been successfully generated revealed that
methionine 93 is likely the gatekeeper residue of AMPKa2
(Figure 1B). To generate an analog-specific version of AMPKa2
(AS-AMPKa2), we mutated methionine 93 to a glycine residue.
We then tested the in vitro kinase activity of WT and AS-AMPKa2
by incubating these kinases with recombinant GST-FOXO3,
a known AMPK substrate (Greer et al., 2007b), in the presence
of ATPgS or a variety of N6-substituted forms of ATPgS.
WT-AMPKa2 uses ATPgS to phosphorylate GST-FOXO3 but is
unable to use N6-modified bulky forms of ATPgS (Figure 1C).
In contrast, AS-AMPKa2 phosphorylates FOXO3 to a lesserMolecextent than WT-AMPKa2 using ATPgS, but is able to use the
N6-substituted bulky forms of ATPgS, particularly N6-(phenethyl)
ATPgS, to phosphorylate FOXO3 in vitro (Figure 1C). Thus,
methionine 93 is the gatekeeper residue in AMPKa2, and
mutation of this residue to a glycine allows AMPKa2 to use
bulky analogs of ATP in vitro.
In Vivo Labeling of Known AMPK Substrates
by AS-AMPKa2
We asked if AS-AMPKa2 could directly phosphorylate
substrates in cells under relatively physiological conditions. To
this end, we expressed HA-tagged versions of WT-AMPKa2 or
AS-AMPKa2, together with the b1 and g1 subunits, as well as
several known M2 (Flag)-tagged AMPK substrates in 293T cells
and stimulated AMPK activity by serum starvation and addition
of 2-deoxyglucose (2DG). N6-(phenethyl) ATPgS was added in
the presence of digitonin, a mild detergent that permeabilizes
the plasma membrane to allow the N6-(phenethyl) ATPgS
to enter cells while largely preserving other intracellular com-
partments. Importantly, these conditions of in vivo labeling
preserved endogenous AMPK signaling (see Figure S1A avail-
able online), although they led to higher AMPK activation than
glucose starvation, a physiological way of activating AMPK (Fig-
ure S1B). To test if substrates could be directly phosphorylated
by AS-AMPKa2 in cells, known AMPK substrates were immuno-
precipitated using an antibody to the M2 tag, and the immune
complexes were analyzed by western blot using the thioP
antibody. These experiments confirmed that AS-AMPKa2
phosphorylates known substrates of AMPK such as CRTC2,
TSC2, and FOXO3 in cells (Figure 1D). Not all proteins that are
highly overexpressed were phosphorylated by AS-AMPKa2
(e.g., SIRT2) (Figure 1D), indicating that AS-AMPKa2 is relatively
specific for its substrates. Some substrates (e.g., CRTC2) were
also labeled to a minor extent in cells expressing WT-AMPKa2
(Figure 1D), suggesting that either WT-AMPKa2 or an endoge-
nous kinase is able to use N6-(phenethyl) ATPgS to phosphory-
late some substrates, albeit to a much lower extent than
AS-AMPKa2. Mutating the gatekeeper site in AMPKa2 does
not significantly alter AMPKa2 site specificity, as a form of
FOXO3 in which all six residues known to be phosphorylated
by AMPK were mutated to alanines (6A FOXO3) (Greer et al.,
2007b) was no longer phosphorylated by AS-AMPKa2 in cells
(Figure 1E). Moreover, endogenous FOXO3 was also phosphor-
ylated by AS-AMPKa2 (Figure 1F). Finally, specific labeling of
FOXO3was observed in a stable cell line with more physiological
levels of AS-AMPKa2 and with endogenous levels of b and
g subunits (Figure S1C). Thus, this chemical genetic approach
is an effective method for identifying direct endogenous sub-
strates of AMPKa2 in a relatively physiological cellular context.
Screen for Direct AMPKa2 Substrates In Vivo
Using AS-AMPKa2
To identify previously unidentified AMPKa2 substrates, we
expressed WT-AMPKa2 or AS-AMPKa2 together with the b1
and g1 subunits in 293T cells (Figure 2A). After activation of
AMPK by serum starvation and 2DG, in vivo phosphorylation
with N6-(phenethyl) ATPgS was performed. We used the thioP
antibody to immunoprecipitate the alkylated protein productsular Cell 44, 878–892, December 23, 2011 ª2011 Elsevier Inc. 879
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were resolved by SDS-PAGE and analyzed by western blot.
More proteins were labeled in cells expressing the AS-AMPKa2
than WT-AMPKa2, both before and after immunoprecipitation
(Figure 2B), indicating that a number of proteins were specifi-
cally phosphorylated by AS-AMPKa2. The entire lanes of pro-
teins immunoprecipitated from cells expressing WT-AMPKa2
and AS-AMPKa2 were cut, the proteins extracted from these
strips were digested with trypsin, and the identity of the resulting
peptides was determined by tandem mass spectrometry (Fig-
ure 2A). Due to the abundance of peptides from the heavy and
light chains of IgG, only proteins with a molecular weight higher
than the IgG heavy chain (55 kDa) were analyzed. Two indepen-
dent biological replicates were performed (Figure 2C). We
focused on proteins for which at least 10-fold more peptides
were identified in cells expressing AS-AMPKa2 compared to
cells expressing WT-AMPKa2. Using this stringent cutoff, we
identified 98 different proteins in the first experiment and 177
different proteins in the second experiment that were labeled
specifically by AS-AMPKa2 (Figure 2C; Table S1). Thirty-two
proteins were identified in both biological replicates (Table 1),
thereby representing the most likely direct substrates of
AMPKa2 in this screen. Among these 32 proteins are three
previously known substrates of AMPK: ACC1 (Witters and
Kemp, 1992; Woods et al., 1994), CRTC2 (Koo et al., 2005;
Shaw et al., 2005), and kinesin light chain 1 (McDonald et al.,
2009) (Table 1). We also identified AMPKa2 as an autophosphor-
ylation substrate, which has been previously reported (Woods
et al., 2003), although it may also be due to the fact that AS-
AMPKa2 was overexpressed. Not all known AMPK substrates
were found (e.g., TSC2, FOXO3, Raptor), possibly due to low
abundance of some proteins or to molecular weights lower
than 55 kDa. Overall, these results indicate that this chemical
genetic screen is sensitive enough to identify previously known
AMPK substrates.
To confirm that the proteins identified in the chemical
genetic screen were indeed substrates of AMPK, we tested
seven of them (protein phosphatase 1 regulatory subunit 12A
[PPP1R12A], PPP1R12C, PAK2, CDC27, brain-specific angio-
genesis inhibitor 1-associated protein 2 [BAIAP2], gephyrin
[GPHN], and CARM1) using the candidate-based approach in
cells described in Figure 1D. Six of these seven proteins were
specifically labeled by AS-AMPKa2 (Figure 2D), indicating that
they are direct substrates of AMPKa2 in human cells. CARM1Figure 1. Generation of an Analog-Specific Version of AMPKa2
(A) Strategy for labeling substrates of analog-specific AMPKa2 (AS-AMPKa2). A
(B) Identification of the gatekeeper amino acid in the ATP-binding pocket of huma
have been created (Allen et al., 2007; Niswender et al., 2002; Polson et al., 2001; U
M.m., Mus musculus; S.c., Saccharomyces cerevisiae.
(C) In vitro kinase assay using WT-AMPKa2 or AS-AMPKa2 immunoprecipit
N6-substituted ATPgS analog as a phosphodonor. Red R, site of N6-alkyl grou
independent experiments.
(D) AS-AMPKa2 phosphorylates known AMPK substrates in cells in the prese
antibodies to M2. Western blots are representative of two independent experime
(E) AS-AMPKa2 no longer phosphorylates M2-FOXO3 with the point mutations in
S626A.
(F) AS-AMPKa2 can phosphorylate endogenous FOXO3 in 293T cells. *, backg
independent experiments.
Molecwas the only protein that was not labeled by AS-AMPKa2
in the validation of the screen (Figure 2D), possibly because
it was coprecipitated with a yet-to-be-identified substrate of
AMPKa2.
To confirm that these substrates are phosphorylated directly
by AMPK, we performed in vitro kinase assays using WT-AMPK
(a mixture of AMPKa1- and -a2-containing complexes) purified
from rat liver, g32P-ATP, and recombinant substrates purified
from E. coli. PPP1R12A, PPP1R12C, PAK2, CDC27, and BAIAP2
were all phosphorylated in vitro by WT-AMPK (Figures 2E, 3E,
and 3G), although CARM1 was not (Figure S2), providing addi-
tional evidence that PPP1R12A, PPP1R12C, PAK2, CDC27,
and BAIAP2 are direct substrates of AMPK. The fact that these
proteins are phosphorylated by WT-AMPK also confirms that
their identification in the chemical genetic screen is unlikely to
have resulted from altered substrate specificity of AS-AMPKa2.
Thus, the chemical genetic screen is an effective approach for
the identification of direct substrates of AMPKa2 in cells, and
could be used for other protein kinases.
AMPKa2 Substrates Are Enriched for Proteins
Involved in Mitosis
Global analysis of AMPKa2 substrates identified in either bio-
logical replicate of our screen using GO, GSEA, and PANTHER
revealed that these AMPK substrates displayed a significant
enrichment for proteins involved in cell cycle, particularly
mitosis and chromosomal segregation (Figure 2F; Table S2
and Table S3). The enrichment for M phase was still highly
significant even when the comparison list was restricted to
proteins larger than 55 kDa (Figure 2G; Table S4). These obser-
vations raise the intriguing possibility that AMPKa2 may coordi-
nate different aspects of mitosis in cells. For example, APC1
and CDC27 are two components of the anaphase-promoting
complex (Peters, 2006). PPP1R12A/MYPT1, PPP1R12B/
MYPT2, and PPP1R12C/MBS85 are known to inhibit the
activity of the MRLC (Ito et al., 2004), a protein that regulates
cytokinesis (Komatsu et al., 2000). The protein kinase PAK2
activates MRLC by direct phosphorylation and is involved in
cytoskeletal reorganization (Tuazon and Traugh, 1984). Finally,
BAIAP2 is a protein required for actin-myosin-dependent
processes and motility (Chauhan et al., 2009). Thus, AMPKa2
may regulate a network of substrates to coordinate chromo-
somal segregation, mitosis, cytokinesis, and cytoskeletal
reorganization.*TPgS, bulky ATP analog. PNBM, p-nitrobenzyl mesylate.
n AMPKa2 by alignment with other kinases for which analog-specific mutants
bersax et al., 2003; Ventura et al., 2006;Weiss et al., 2000).H.s.,Homo sapiens;
ated from 293T cells with GST-FOXO3 as a substrate and the indicated
p attachment 1–4 indicated at right. Western blots are representative of two
nce of N6-(phenethyl) ATPgS. Substrates were immunoprecipitated with the
nts.
the AMPK phosphorylation sites in cells. 6A, T179A/S399A/S413A/S55A/S588/
round band present in all samples. Western blots are representative of three
ular Cell 44, 878–892, December 23, 2011 ª2011 Elsevier Inc. 881
Figure 2. Identification of Direct Substrates of AMPKa2 in Cells by a Chemical Genetic Screen
(A) Strategy for identifying endogenous direct substrates of AS-AMPKa2 in cells.
(B) Phosphorylation of endogenous AMPKa2 substrates in 293T cells expressing WT-AMPKa2 or AS-AMPKa2. (Left panel) Western blot of lysates run before
immunoprecipitation (input). (Right panel) Western blot of proteins released from the beads after the immunoprecipitation (eluate).
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Table 1. List of AMPKa2 Substrates
Accession Number Experiment 1 Experiment 2 Protein Name
O14974 32 23 Protein phosphatase 1 regulatory subunit 12A
Q13085 13 12 Acetyl-CoA carboxylase 1
Q9H1A4 7 14 Anaphase-promoting complex subunit 1
P30260 11 9 Cell division cycle protein 27 homolog
Q13439 7 10 Golgin subfamily A member 4
Q9BZL4 5 10 Protein phosphatase 1 regulatory subunit 12C
Q9UHR4 10 4 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1
P11717 6 8 Cation-independent mannose-6-phosphate receptor precursor
Q92973 7 6 Transportin-1
Q9UQB8 11 1 Brain-specific angiogenesis inhibitor 1-associated protein 2
Q6WKZ4 10 2 Rab11 family-interacting protein 1
Q9UKE5 6 6 TRAF2 and NCK-interacting protein kinase
Q9Y2A7 4 5 NCK-associated protein 1
Q9Y6M7 5 4 Sodium bicarbonate cotransporter 3
Q9NQX3 2 5 Gephyrin
Q8N4C8 2 5 Misshapen-like kinase
O95486 4 2 Protein transport protein SEC24A
Q15459 2 4 Splicing factor 3 subunit 1
Q13625 3 2 Apoptosis-stimulating of p53 protein 2
Q07866 2 3 Kinesin light chain 1
Q86X10 2 3 Protein KIAA1219
Q13177 3 2 Serine/threonine-protein kinase PAK 2
P54646 2 2 50-AMP-activated protein kinase catalytic subunit a-2
P63010 1 3 AP-2 complex subunit b-1
Q53ET0 2 2 CREB-regulated transcription coactivator 2
Q86X55 3 1 Histone-arginine methyltransferase CARM1
Q9Y4L1 1 3 Hypoxia up-regulated protein 1 precursor
O75153 2 2 Putative eukaryotic translation initiation factor 3 subunit
O60763 1 1 General vesicular transport factor p115
Q06210 1 1 Glucosamine-fructose-6-phosphate aminotransferase [isomerizing] 1
P07196 1 1 Neurofilament light polypeptide
O60237 1 1 Protein phosphatase 1 regulatory subunit 12B
Numbers indicate the number of peptides found for each protein in each biological replicate. Proteins are listed in descending order according to the
number of peptides identified. Bold, substrates validated in this study. Italics, previously identified substrates of AMPK. The full list of proteins identified
in each biological replicate is provided in Table S1.
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AMPKa2 Substrates
We identified the specific residues phosphorylated by
AMPKa2 in PPP1R12C, BAIAP2, CDC27, and PAK2. Analysis
of these proteins using Scansite with an optimized AMPK
phosphorylation consensus motif derived from Gwinn et al.(C) Results of two independent labeling and substrate isolation experiments. Red
AS-AMPKa2, respectively. The numbers indicate the number of proteins identified
provided in Table S1.
(D) Validation of six AMPKa2 substrates identified in the chemical genetic screen
similar to that of the IgG heavy chain. Western blots are representative of at leas
(E) In vitro phosphorylation of five AMPKa2 substrates identified in the chemical g
Western blots are representative of two independent experiments.
(F) SelectedGeneOntology (GO) terms for AMPKsubstrates identifiedby the chem
(G)SelectedGO terms for AMPKsubstrateswhencompared to proteinswithmolec
Molec(2008) revealed residues that conformed to the AMPK
consensus motif in each substrate (Figure 3A). We mutated
these sites to nonphosphorylatable alanines and determined
the extent of phosphorylation of each mutant using the
candidate-based in vivo labeling method. Using this approach
for PPP1R12C, BAIAP2, and CDC27, we found that mutationand blue circles represent proteins found in cells expressing WT-AMPKa2 and
in each category. The full list of proteins identified in each biological replicate is
by in vivo labeling with AS-AMPKa2. Note that BAIAP2 has a molecular weight
t two independent experiments.
enetic screen by purified WT-AMPK in the presence of radiolabeled g32P-ATP.
ical genetic screen. The full list of enrichedGO terms is in Table S2 andTable S3.
ularweights greater than55 kDa. The full list of enrichedGO terms is in TableS4.
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Figure 3. Identification of AMPK Phosphorylation Sites in Four AMPKa2 Substrates
(A) Scansite prediction of potential AMPK phosphorylation sites. The AMPK consensus phosphorylation motif, derived from Gwinn et al. (2008), is shown on the
top in single letter amino acid code. Positions denoted as ‘‘X’’ showed some additional modest selectivities among amino acids but lack the strong discrimination
shown in the specified positions. Known AMPK phosphorylation sites in ACC1 and FOXO3 are shown as comparisons.
(B–D) In vivo identification of AMPKa2 phosphorylation sites in PPP1R12C (B), BAIAP2 (C), and CDC27 (D). Analysis was carried out as in Figure 1D.
Molecular Cell
AMPK Phosphorylates Substrates Involved in Mitosis
884 Molecular Cell 44, 878–892, December 23, 2011 ª2011 Elsevier Inc.
Molecular Cell
AMPK Phosphorylates Substrates Involved in Mitosisof a single serine to alanine (S452, S366, and S379, respec-
tively) resulted in an almost complete loss of AMPK phosphor-
ylation in these proteins (Figures 3B–3D). The mutation of
these sites also diminished phosphorylation of PPP1R12C,
BAIAP2, and CDC27 by WT-AMPK in vitro (Figure 3E), indi-
cating that the specificity of AMPK for these sites is not
affected by the gatekeeper methionine to glycine mutation at
position 93 in AS-AMPKa2. Thus, S452, S366, and S379,
which are part of an AMPK consensus motif, are the major
AMPKa2 phosphorylation sites in PPP1R12C, BAIAP2, and
CDC27, respectively.
PAK2 has several potential AMPK phosphorylation sites
(Figure 3A). Tandem mass spectrometry analysis of PAK2
phosphorylated in vitro by WT-AMPK revealed that S20, S55,
S141, and S197 of PAK2 were phosphorylated in vitro by
AMPK (Table S5). The mutation of serine 20 to an alanine
abolished the phosphorylation of PAK2 by AS-AMPKa2 in cells
and by WT-AMPK in vitro, whereas the mutation of the other
serines had no or little impact (Figures 3F and 3G). Thus, S20,
which is part of an AMPK consensus motif, is the major site of
AMPK phosphorylation on PAK2.
AMPK Phosphorylates PPP1R12C and PAK2
in Human Cells
We focused on AMPK substrates potentially involved in mitosis.
The PPP1R12 family of protein phosphatase regulatory subunits
stood out because three members of this family were identified
in the screen. PPP1R12C limits the phosphorylation of MRLC
(Ito et al., 2004), a protein involved in mitosis (Komatsu et al.,
2000). Intriguingly, the kinase PAK2, which was also found in
the screen, promotes MRLC phosphorylation (Chew et al.,
1998; Tuazon and Traugh, 1984). Thus, AMPK might regulate
a network of antagonistic signaling molecules to coordinate
mitotic progression.
To determine if AMPK promotes the phosphorylation of
PPP1R12C in cells, we generated a phospho-specific antibody
to S452 of PPP1R12C (P-S452). This P-S452 antibody was
specific to the phosphorylated form of PPP1R12C in that it
recognized WT-PPP1R12C in the presence of AMPK but did
not recognize the PPP1R12C S452A mutant or WT-PPP1R12C
that had not been incubated with AMPK (Figure S3A). The
P-S452 antibody was also specific to the endogenous phos-
phorylated form of PPP1R12C in human cells, as shown using
siRNA or shRNA to PPP1R12C (Figure S3B, Figure 4F).
Using this antibody, we showed that phosphorylation of
M2-PPP1R12C at S452 was enhanced when 293T cells were
treated with the AMPK activator 2DG and decreased when cells
were treated with compound C, a chemical inhibitor of AMPK
(Zhou et al., 2001) (Figure 4A). The phosphorylation of endoge-
nous PPP1R12C at S452 in 293T cells was increased in response
to 2DG or the highly specific AMPK activator A-769662 (Cool
et al., 2006; Goransson et al., 2007; Sanders et al., 2007a) (Fig-
ure 4B). The phosphorylation of M2-PPP1R12C at S452 was(E) In vitro validation of AMPK phosphorylation sites in PPP1R12C, BAIAP2, and
(F) In vivo testing of putative phosphorylation sites identified by tandem mass sp
(G) In vitro validation of AMPK phosphorylation sites in PAK2. Kinase assay was
experiments.
Molecalso increased in response to 2DG and A-769662 in U2OS cells,
and this phosphorylation was reduced when both catalytic
subunits of AMPK were knocked down with siRNA (Figure 4C).
Similar results were observed with endogenous PPP1R12C
(Figure 4D; Figure S3C). Importantly, endogenous PPP1R12C
phosphorylation at S452 was increased in response to glucose
or nutrient starvation (Figures 4E and 4F), which are physiological
ways of activating AMPK. Similar results were obtained for
PAK2 (Figure S4). Together, these results indicate that AMPK
phosphorylates endogenous PPP1R12C at S452 and PAK2 at
S20 in human cells.
Phosphorylation by AMPK Promotes the Interaction
between PPP1R12C and 14-3-3z
We examined the consequences of AMPK phosphorylation on
PPP1R12C. PPP1R12A, another regulatory subunit of myosin
phosphatase, has been shown to interact with 14-3-3 (Koga
and Ikebe, 2008). We therefore asked if phosphorylation
by AMPK affects a potential interaction between PPP1R12C
and 14-3-3. Coimmunoprecipitation studies revealed that
PPP1R12C interacted with 14-3-3z in 293T cells (Figure 5A).
Interestingly, the interaction between PPP1R12C and 14-3-3z
was abolished bymutation of serine 452 to alanine in PPP1R12C
(Figure 5A). In contrast, this mutation did not affect the interac-
tion between PPP1R12C and the catalytic phosphatase subunit
PP1Cb (Figure S5A). The interaction between PPP1R12C and
14-3-3z was decreased when AMPKa1 and a2 were both
knocked down (Figure 5B). Conversely, the interaction between
PPP1R12C and 14-3-3z was increased in response to the
specific AMPK activator A-769662 and to glucose starvation
(Figure 5C). Collectively, these results show that phosphorylation
of S452 promotes the interaction between PPP1R12C and 14-3-
3z but does not regulate the interaction with the catalytic subunit
of the phosphatase (Figure 5D). The interaction be-
tween PPP1R12C and 14-3-3z may inactivate the PPP1R12C-
containing phosphatase complex in vivo.
AMPK Indirectly Regulates MRLC Phosphorylation,
in Part via PPP1R12C and PAK2
PPP1R12C and PAK2 directly regulateMRLCphosphorylation at
S19 in an opposing manner (Matsumura and Hartshorne, 2008;
Tuazon and Traugh, 1984). We asked whether AMPK affects
MRLC phosphorylation in cells. Stimulation of cells with the
AMPK activator A-769662 led to an increased phosphorylation
of endogenous MRLC at S19, which can be visualized either
by an antibody to phospho-S19 or to phospho-T18/S19
(Figure 5E). Conversely, knocking down both AMPKa1 and a2
resulted in a modest but significant (p = 0.0012) reduction in
M2-MRLC phosphorylation at S19 in 293T cells (Figures S5B
and S5C). MRLC was not phosphorylated directly by AMPK
in vivo, as shown by in vivo labeling using AS-AMPKa2 (Fig-
ure S5D). These results support the notion that AMPK affects
MRLC phosphorylation at S19 indirectly.CDC27. Kinase assays were carried out as in Figure 2E.
ectrometry for PAK2. Analysis was carried out as described in Figure 1D.
carried out as in Figure 2E. All panels are representative of two independent
ular Cell 44, 878–892, December 23, 2011 ª2011 Elsevier Inc. 885
Figure 4. AMPK Promotes the Phosphorylation of PPP1R12C in Human Cells
(A) Phosphorylation of M2-PPP1R12C at S452 is enhanced in response to the AMPK activator 2-deoxyglucose (2DG) and inhibited by the AMPK inhibitor
compound C (CC) in 293T cells. Cell lysates were analyzed by western blot.
(B) Phosphorylation of endogenous PPP1R12C at S452 is stimulated in response to 2DG or A-769662 (A) in 293T cells. Cell lysates were analyzed by
western blot.
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AMPK Phosphorylates Substrates Involved in MitosisWe next tested if AMPK regulates MRLC phosphorylation
via PPP1R12C and PAK2. The increase in MRLC S19 phosphor-
ylation in response to A-769662 was slightly, but reproducibly,
reduced in cells expressing the nonphosphorylatable form of
PPP1R12C, S452A (Figure 5F; Figure S5E). Expression of
a mutant of PAK2 at the AMPK phosphorylation site (S20A)
strongly reduced the phosphorylation of MRLC in response to
AMPK activation (Figure 5G). Phosphorylation by AMPK did
not affect PAK2’s activity toward MRLC in vitro (M.R.B. and
A.B., unpublished data), although it may alter PAK2’s accessi-
bility to substrates in cells. Glucose starvation, a physiological
way of activating AMPK, led to an increase in the phosphoryla-
tion of endogenous AMPK, PPP1R12C, PAK2, and MRLC
(Figure 4E). Together, these data suggest that AMPK indirectly
regulates MRLC phosphorylation in part by phosphorylating
PPP1R12C and PAK2.
AMPK Activity and PPP1R12C Phosphorylation Are High
in Mitotic Cells
Given the enrichment in AMPK substrates for proteins involved in
mitosis, we examined the phosphorylation of endogenous
AMPK, PPP1R12C, and PAK2 throughout mitosis. U2OS cells
were synchronized with the prometaphase blockers monastrol
or nocodazole, and cells were released from the block for
different lengths of time. Phosphorylation of AMPK at T172
was high in prometaphase of mitosis and decreased 1 hr after
release from the monastrol or nocodazole block (Figure 6A;
Figures S6A and S6B). Phosphorylation of PPP1R12C at S452
was also high in prometaphase and tended to decrease 1 hr after
the release from the monastrol or nocodazole block, before
significantly increasing at the end of mitosis (Figure 6A; Figures
S6A and S6B). In contrast, phosphorylation of PAK2 at S20
was not significantly altered during mitotic progression (Fig-
ure 6A; Figures S6A and S6B).
To independently follow AMPK activity in mitosis, we used
fluorescence resonance energy transfer (FRET) in live cells with
a fluorescence reporter for AMPK activity, AMPKAR (Tsou
et al., 2011). AMPKAR fluorescence reached a peak just before
U2OS cells divide (Figure 6B), indicating that AMPK is highly
active in the early phases of mitosis. The levels of AMPK activity
slightly decreased as U2OS cells underwent cytokinesis (Fig-
ure 6B). Similar results were observed in other cell types (Figures
S6C and S6D). Together, these results indicate that AMPK
activity and the phosphorylation of PPP1R12C are high in mitotic
cells and decrease as cells progress through mitosis.
Perturbation of AMPK Activity Impairs Mitosis
Progression
To test the function of AMPK activity in mitosis, we acutely
perturbed AMPK activity after synchronizing cells in mitosis(C) Phosphorylation of M2-PPP1R12C at S452 in U2OS cells in response to activa
to both AMPKa1 and a2 (+) compared to scrambled control siRNAs (). Cell lysa
(D) The phosphorylation of endogenous PPP1R12C at S452 in response to A-76
and AMPKa2 (AMPKa1/a2) compared to control cells (vector). Western blots are
(E and F) Glucose and nutrient starvation promote the phosphorylation of endo
are representative of two independent experiments.
Molecand counted the number of multinucleated cells. Compound C,
an inhibitor of AMPK, led to a significant increase in the number
of multinucleated cells, similar to BTO-1, an inhibitor of the
mitotic kinase Polo-like kinase (PLK) (Figure 6C, Figure S7A). In
contrast, an inhibitor of PI3K (LY-294002) had no effect on the
number of multinucleated cells (Figure 6C). Because compound
C has other targets in addition to AMPK (Bain et al., 2007;
Vogt et al., 2011), we used alternative approaches to perturb
AMPK. U2OS cells expressing shRNA to both AMPKa1 and
AMPKa2 exhibited a slight increase in multinucleated cells at
some time points after release from a mitotic block, although
they did not display an overall increase in multinucleated cells
(Figure S7B; B.E.S. and A.B., unpublished data). Interestingly,
acutely activating AMPK with A-769662, a highly specific
activator of AMPK, significantly increased the number of multi-
nucleated cells (Figure 6C). Activating AMPK with metformin
has also been found to increase the number of multinucleated
cells (Vazquez-Martin et al., 2009b). These observations are
reminiscent of what has been shown for important regulators
of mitosis (e.g., Mad2, PLK), whose inhibition or activation
results in mitotic defects (Brennan et al., 2007; Conn et al.,
2000; Michel et al., 2004; Sotillo et al., 2007). Collectively, these
experiments suggest that proper AMPK activity is important for
mitotic progression.
AMPK Phosphorylation Site in PPP1R12C Affects
Mitotic Progression
We asked if the regulation of PPP1R12C by AMPK is impor-
tant for mitosis completion. U2OS cells stably expressing
PPP1R12C S452A had a significant increase in the percentage
of multinucleated cells compared to cells expressing WT-
PPP1R12C (Figure S7C; Figure 6D) and to cells expressing
the empty vector (Figure S7D). These results suggest that the
mutation of the AMPK phosphorylation site in PPP1R12C
results in defects in mitotic progression and cytokinesis. WT
PPP1R12C also led to an increase in the percentage of multinu-
cleated cells, possibly because overexpressed WT PPP1R12C
may no longer be phosphorylated by endogenous AMPK and
may act as a dominant negative. In contrast, expression of
WT or S20A PAK2 did not result in an increase in multinucle-
ated cells compared to control cells (Figure S7E). Thus, the
phosphorylation of PPP1R12C by AMPKa2 appears to be
more important for proper cytokinesis than phosphorylation of
PAK2. Interestingly, cells expressing S452A PPP1R12C also
had an overall slight, but significant, increase in the percentage
of cells in anaphase with lagging chromosomes compared to
cells expressing WT PPP1R12C (Figures S8A and S8B), which
is likely a result of defects in chromosomal segregation. Thus,
AMPK phosphorylation of PPP1R12C might coordinate chro-
mosomal segregation and cytokinesis.tion of AMPK by 2DG or A-769662 (A) is diminished in the presence of siRNAs
tes were analyzed by western blot.
9662 (A) is diminished in U2OS cells expressing an shRNA to both AMPKa1
representative of two independent experiments.
genous PPP1R12C at S452 and PAK2 at S20 in U2OS cells. Western blots
ular Cell 44, 878–892, December 23, 2011 ª2011 Elsevier Inc. 887
Figure 5. AMPK Phosphorylation of PPP1R12C and PAK2 Affects the Interaction between PPP1R12C and 14-3-3z and MRLC
Phosphorylation
(A) M2-14-3-3z coimmunoprecipitates with WT, but not S452A, T7-PPP1R12C in 293T cells stimulated with 2-deoxyglucose (2DG). Western blots are
representative of three independent experiments.
(B) M2-14-3-3z no longer coimmunoprecipitates withWT PPP1R12C in 293T cells expressing an shRNA to both AMPKa1 and AMPKa2 (AMPKa1/a2) in response
to 2-deoxyglucose (2DG). Western blots are representative of two independent experiments.
(C) The interaction between PPP1R12C and 14-3-3z is increased in response to AMPK activation by 2DG for 5 min, A-769662 (A) for 1 hr, or glucose starvation
(GS) for 2 hr. Immune complexes were analyzed by western blot.
(D) Model summarizing the effect of AMPK phosphorylation on the interaction between PPP1R12C and 14-3-3z.
(E) AMPK activation with A-769662 (A) leads to an increase in MRLC phosphorylation at S19 and T18/S19 in U2OS cells. Western blots are representative of
three independent experiments.
(F) The increase in MRLC S19 phosphorylation in response to A-769662 (A) is slightly, but significantly, reduced in U2OS cells expressing PPP1R12C S452A.
Western blots are representative of four independent experiments. Quantification is presented in Figure S5E.
(G) Phosphorylation of MRLC at S19 is reduced in U2OS cells expressing PAK2 S20A in response to A-769662 (A). Western blots are representative of two
independent experiments.
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Figure 6. AMPK Activity and PPP1R12C Phosphorylation Are Elevated in Mitosis and Are Important for Mitotic Progression
(A) Phosphorylation of endogenous AMPK, PPP1R12C, and PAK2 in U2OS cells synchronized by thymidine followed bymonastrol block and collected at different
time points after release from the block (blue bar). Cell lysates were analyzed by western blot.
(B) AMPK FRET signal is high when cells enter mitosis and starts to decrease around the time the cells initiated cytokinesis in U2OS cells expressing AMPKAR,
a fluorescent reporter for AMPK activity. AMPK activity was measured at 10 min intervals. Red, increased AMPK activity.
(C) U2OS cells were synchronized by thymidine followed by monastrol block, and chemicals were added 1.5 hr after the release from the monastrol block (blue
bar) and replating of mitotic cells. Cells were fixed 4.5 hr after the addition of chemicals. The number of multinucleated cells was normalized to the number
observed in nontreated control cells for each experiment. Means ± SEM of three independent experiments are shown, except for the LY-294002 condition, which
represents two independent experiments. *p < 0.05 by one-way ANOVA analysis. ns, not statistically significant.
(D) U2OS cells expressingWT or S452A PPP1R12Cwere synchronized by thymidine block. Cells were fixed at the indicated time after release from the block (blue
bar). Percentage of multinucleated cells in each condition is shown. Means ± SEM for three independent stainings of a single synchronization experiment. *p <
0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA, with Bonferroni post hoc tests.
(E) AMPK directly phosphorylates a number of substrates involved in coordinating different aspects of mitosis.
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Molecular Cell
AMPK Phosphorylates Substrates Involved in MitosisOur findings indicate that AMPKa2, a critical energy-sensing
protein kinase, directly phosphorylates a series of substrates
enriched for proteins involved in mitosis completion and chro-
mosomal segregation. AMPK activity and the phosphorylation
of one of its substrates, PPP1R12C, are elevated in mitosis.
Altering AMPK activity duringmitosis impairsmitotic completion.
Cells expressing a mutant of PPP1R12C that can no longer be
phosphorylated by AMPK also exhibit mitotic defects. Impor-
tantly, the residue phosphorylated by AMPK in PPP1R12C is
not part of a consensus for the other kinases targeted by
compound C or for well-known mitotic kinases (e.g., PLK,
CDK1). Taken together, these data support the notion that
AMPK regulates mitotic completion.
DISCUSSION
The chemical genetic screen presented here provides a rapid
and physiological means of identifying direct in vivo substrates
of a protein kinase in cells, which could be applied to other
kinases. Our screen was performed in gently permeabilized
cells, thus preserving, at least in part, the physiological content
of cells. A potential limitation of this screen is that it did not
identify all of the previously known AMPK substrates (e.g.,
TSC2, FOXO3). Improved immunoprecipitation efficiency with
the thioP antibody or the use of a peptide capture approach
(Blethrow et al., 2008) should help the identification of low-abun-
dant and low molecular weight substrates. Another limitation is
that the screen was performed in cells overexpressing the AS-
AMPKa2, which could lead to artifactual phosphorylation.
However, independent confirmation of the phosphorylation of
two endogenous substrates (PPP1R12C and PAK2) in cells
supports the notion that this chemical genetic approach is a valid
way of identifying physiologically relevant substrates of a protein
kinase.
While previously known substrates of AMPK have largely
implicated this kinase in metabolism, G1 arrest, and transcrip-
tional regulation, the substrates identified here show a signifi-
cant enrichment for proteins involved in the regulation of
mitosis. Phosphorylation of PPP1R12C at the AMPK site
appears to be important for the normal completion of mitosis
and chromosomal segregation in mammalian cells. We do not
rule out the possibility that the effects of AMPK activity on
cytokinesis are dependent on substrates other than PPP1R12C
or that the effects of phosphorylation of S452 of PPP1R12C
on mitosis are dependent on other kinases. For example, the
network of AMPK substrates involved in mitosis may extend
to APC1 and CDC27, two components of the anaphase-
promoting complex identified in our screen. Our results are
consistent with the G2/M arrest observed in several cell types
lacking AMPK, in Drosophila and mice (Bettencourt-Dias
et al., 2004; Dasgupta and Milbrandt, 2009; Gwinn et al.,
2008), the defects in chromosomal segregation in Drosophila
larvae lacking AMPK (Lee et al., 2007), and the observation
that AMPK is highly phosphorylated at the mitotic apparatus
in cells (Vazquez-Martin et al., 2009a, 2009c, 2011). Our results
further extend prior studies by proposing a mechanism of
action for AMPK in the control of mitosis. Thus, AMPK may
control a network of proteins involved in coordinating various890 Molecular Cell 44, 878–892, December 23, 2011 ª2011 Elsevieraspects of mitotic completion, including anaphase and
cytokinesis.
Energy deprivation, by regulating AMPK, could promote the
completion of previously initiated mitosis to allow the cell to
arrest at the G1/S checkpoint and await more favorable nutrient
conditions. Alternatively, AMPK could play a role in mitosis
regardless of the energy status of the cell. In fact, AMPK phos-
phorylation has been shown to increase in mitosis indepen-
dently of the energy status of the cell (Vazquez-Martin et al.,
2009a), and the percentage of multinucleated cells did not
appear to change when cells were deprived of glucose
(M.R.B. and A.B., unpublished data). Phosphorylation of
substrates involved in orchestrating mitosis and cytoskeletal
rearrangements by AMPK could result in coordinating AMPK
activity with other cellular fates tightly associated with the birth
of new cells, such as polarity and migration. Coordinated
completion of mitosis, polarization, and migration by AMPK
could be critical for a number of physiological functions,
including stem cell homeostasis, and for preventing patholog-
ical conditions, such as cancer.
EXPERIMENTAL PROCEDURES
Chemical Genetic Screen for AMPK Substrates in Cells
293T cells (2 3 106 cells/10 cm dish) were transfected with 6.67 mg of
M2-WT-AMPKa2 or AS-AMPKa2, 6.67 mg HA-AMPKb1, and 6.67 mg
HA-AMPKg1 using the calcium phosphate method. Twenty-five 10 cm plates
were used for each condition. Forty-eight hours after transfection, the cells
were incubated for 2 hr in serum-free DMEM, prior to stimulation with
100 mM 2DG for 5 min. Following stimulation, 500 ml of phosphorylation
buffer (20 mM HEPES [pH 7.3], 100 mM KOAc, 5 mM NaOAc, 2 mM
MgOAc2, 1 mM EGTA, 10 mM MgCl2, 0.5 mM DTT, 5 mM creatine phos-
phate [Calbiochem], 57 mg/ml creatine kinase [Calbiochem], 30 mg/ml digi-
tonin, 5 mM GTP, 0.1 mM ATP, 0.1 mM N6-[phenethyl] ATPgS, 0.45 mM
AMP, 13 phosphatase inhibitor cocktail I and II [Sigma], and 13 complete
protease inhibitors, EDTA-Free [Roche]) was added. After shaking gently
for 20 min at room temperature, the cells for each condition were pooled
and EDTA was added to a concentration of 20 mM. The cells were then
sonicated six times at 4.0 W for 30 s, and the cell pellets were removed
by centrifugation. P-nitrobenzyl mesylate (PNBM, Epitomics) was added to
the lysates to a final concentration of 2.5 mM, and the samples were then
incubated for 1 hr at room temperature. PNBM was removed, and samples
were exchanged onto RIPA buffer (100 mM Tris [pH 8], 300 mM NaCl, 2%
NP-40, 0.2% SDS, and 20 mM EDTA) using PD-10 columns (Amersham).
The protein fractions were then precleared by incubation with protein G
agarose beads (Sigma) for 3 hr at 4C. The precleared extracts were
incubated with protein G agarose coupled to the thioP antibody and
incubated at 4C overnight. The beads were washed five times in RIPA
buffer, and the bound proteins were eluted with SDS sample buffer. Proteins
were resolved by SDS-PAGE and visualized by staining with colloidal blue
(Invitrogen).
Mitosis Assay on Stable Cell Lines
U2OS cells stably expressing empty vector, M2-PPP1R12C (WT or S452A),
or M2-PAK2 (WT or S20A) were plated at 40% confluence and blocked with
thymidine (Sigma, 2.5 mM) for 18 hr followed by release from the block by
washing twice in fresh media. Cells were fixed in 4% paraformaldehyde at
various time points following release and costained with DAPI and the
DM1A antibody to stain microtubules or with wheat germ agglutinin (Alexa
Fluor 594). The percentage of multinucleated cells was determined for
each condition using fluorescence microscopy by counting at least 300–
400 cells per condition. A cell was considered multinucleated when it con-
tained more than one nucleus and there was no visible membrane separation
between nuclei.Inc.
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